Koen Totté
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Koen Totté has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Alexander Bodelier
Department of Gastroenterology and Hepatology Amphia Ziekenhuis Breda the Netherlands
1 shared publication- Annemarie Charlotte de Vries
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
1 shared publication - Benjamin Mordmüller
Radboudumc Afdeling Medische Microbiologie, Nijmegen, Gelderland, The Netherlands
1 shared publication Christa E. van der Gaast-De Jongh
Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands
1 shared publicationD. van der Horst
Crohn & Colitis NL, Woerden, The Netherlands
1 shared publicationDaniela M. Ferreira
Liverpool School of Tropical medicine, Respiratory Infection Group, Liverpool, United Kingdom of Great Britain and Northern Ireland; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom of Great Britain and Northern Ireland
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-12
Patient Perspectives to Inform Co-creation of Wearable-Derived Digital Biomarkers for Early Flare Detection and Management in IBD: A Survey-Based Study
Purpose Wearable-derived digital biomarkers represent a new frontier in remote management of inflammatory bowel disease (IBD). They may enable continuous disease surveillance and early flare detection while reducing reliance on questionnaire-based remote monitoring. However, successful implementation into clinical practice critically depends on patient acceptance and perceived relevance. To guide patient-centered digital health strategies, we aimed to investigate patient perspectives on digital biomarkers for (early) flare detection. Methods A nationwide cross-sectional survey-based study was conducted among patients with IBD (≥ 16 years) in the Netherlands. A study-specific questionnaire was distributed through the Dutch patient organization Crohn & Colitis NL to assess acceptance, preferences, and perspectives on the use of wearable technology for flare detection. Results 1,080 participants were included: 72.5% women, 53.4% aged >50 years, and 28.7% current wearable users. Overall, 88% considered remote monitoring for flare detection potentially useful, and over 90% believed wearables could support this. Motivations for using wearables included flare detection, better understanding of symptoms, and health monitoring. User-friendliness, clear alerts, and time efficiency were key device preferences, and smartwatches were the preferred wearable device. Shorter disease duration (pp=0.029), younger age (p=0.016), and current wearable use (p<0.001) were identified as predictors for willingness to use wearables. Conclusion Patients with IBD value wearables for flare detection and disease-monitoring. Most participants expressed willingness to use digital biomarkers and believed that wearables could support routine care. Incorporating patient preferences into digital biomarker development will likely improve patient acceptance and adherence to remote monitoring.
- 10 September 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-12
Open AccessPatient Perspectives to Inform Co-creation of Wearable-Derived Digital Biomarkers for Early Flare Detection and Management in IBD: A Survey-Based Study
Purpose Wearable-derived digital biomarkers represent a new frontier in remote management of inflammatory bowel disease (IBD). They may enable continuous disease surveillance and early flare detection while reducing reliance on questionnaire-based remote monitoring. However, successful implementation into clinical practice critically depends on patient acceptance and perceived relevance. To guide patient-centered digital health strategies, we aimed to investigate patient perspectives on digital biomarkers for (early) flare detection. Methods A nationwide cross-sectional survey-based study was conducted among patients with IBD (≥ 16 years) in the Netherlands. A study-specific questionnaire was distributed through the Dutch patient organization Crohn & Colitis NL to assess acceptance, preferences, and perspectives on the use of wearable technology for flare detection. Results 1,080 participants were included: 72.5% women, 53.4% aged >50 years, and 28.7% current wearable users. Overall, 88% considered remote monitoring for flare detection potentially useful, and over 90% believed wearables could support this. Motivations for using wearables included flare detection, better understanding of symptoms, and health monitoring. User-friendliness, clear alerts, and time efficiency were key device preferences, and smartwatches were the preferred wearable device. Shorter disease duration (pp=0.029), younger age (p=0.016), and current wearable use (p<0.001) were identified as predictors for willingness to use wearables. Conclusion Patients with IBD value wearables for flare detection and disease-monitoring. Most participants expressed willingness to use digital biomarkers and believed that wearables could support routine care. Incorporating patient preferences into digital biomarker development will likely improve patient acceptance and adherence to remote monitoring.
- Open Access
Long‐Term Effectiveness of Ustekinumab in Patients With Ulcerative Colitis: Real‐World Data From the IBDREAM and Initiative on Crohn and Colitis Registries
Background: Clinical trials have demonstrated the long‐term efficacy of ustekinumab in the treatment of ulcerative colitis (UC). However, real‐world data on its long‐term effectiveness beyond 1 year of follow‐up remain limited. Methods: This multicenter cohort study evaluated the effectiveness of ustekinumab in adults with UC treated in routine clinical practice for up to 4 years. Data were obtained from two prospective Dutch registries: IBDREAM and the ICC registry. The primary outcome was corticosteroid‐free remission at year 3, with remission defined as a hierarchical, composite endpoint based on endoscopic, biochemical, and clinical parameters. Subgroup analysis was performed in patients with difficult‐to‐treat IBD, defined as prior failure of ≥ 2 advanced therapies with different mechanisms of action. Secondary outcomes included dose escalation and safety. Results: A total of 198 patients were included; median age was 49 years, 48% were women, median disease duration was 8 years, and 42.4% had difficult‐to‐treat IBD. At years 2, 3, and 4, 35.8% (49/137), 34.3% (34/99), and 26.6% (17/64) of patients were in corticosteroid‐free remission. Among patients in corticosteroid‐free remission at week 12 ( n = 83), 50.0% remained in remission at year 3. Corticosteroid‐free remission rates at year 3 in patients with difficult‐to‐treat IBD and other patients were 19.2% and 51.1%, respectively. One‐hundred‐seven adverse events were recorded in 64 patients, including six serious adverse events. Conclusion: These real‐world data confirm the effectiveness of ustekinumab in inducing and maintaining remission for up to 4 years in UC. The medication was particularly effective in patients with limited prior exposure to advanced therapies. Results support the established safety profile of ustekinumab.
Open AccessLong‐Term Effectiveness of Ustekinumab in Patients With Ulcerative Colitis: Real‐World Data From the IBDREAM and Initiative on Crohn and Colitis Registries
Background: Clinical trials have demonstrated the long‐term efficacy of ustekinumab in the treatment of ulcerative colitis (UC). However, real‐world data on its long‐term effectiveness beyond 1 year of follow‐up remain limited. Methods: This multicenter cohort study evaluated the effectiveness of ustekinumab in adults with UC treated in routine clinical practice for up to 4 years. Data were obtained from two prospective Dutch registries: IBDREAM and the ICC registry. The primary outcome was corticosteroid‐free remission at year 3, with remission defined as a hierarchical, composite endpoint based on endoscopic, biochemical, and clinical parameters. Subgroup analysis was performed in patients with difficult‐to‐treat IBD, defined as prior failure of ≥ 2 advanced therapies with different mechanisms of action. Secondary outcomes included dose escalation and safety. Results: A total of 198 patients were included; median age was 49 years, 48% were women, median disease duration was 8 years, and 42.4% had difficult‐to‐treat IBD. At years 2, 3, and 4, 35.8% (49/137), 34.3% (34/99), and 26.6% (17/64) of patients were in corticosteroid‐free remission. Among patients in corticosteroid‐free remission at week 12 ( n = 83), 50.0% remained in remission at year 3. Corticosteroid‐free remission rates at year 3 in patients with difficult‐to‐treat IBD and other patients were 19.2% and 51.1%, respectively. One‐hundred‐seven adverse events were recorded in 64 patients, including six serious adverse events. Conclusion: These real‐world data confirm the effectiveness of ustekinumab in inducing and maintaining remission for up to 4 years in UC. The medication was particularly effective in patients with limited prior exposure to advanced therapies. Results support the established safety profile of ustekinumab.
- Open Access
- 18 February 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (3) , 106704
Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection
- 18 February 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (3) , 106704
Open AccessControlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection